These data indicate that in human acute myeloid leukemia (AML) cells, 24 h post-dTAG-13 treatment is the ideal time point for gene expression analysis as we observe complete degradation of FKBP-SETD1A prior to significant cell-cycle arrest and apoptosis. Here, SETD1A is linked to acute myeloid leukemia.